**Name of journal: World Journal of Hepatology**

**ESPS Manuscript NO: 12661**

**Columns:** **TOPIC HIGHLIGHT**

WJH 6th Anniversary Special Issues (2): Hepatocellular carcinoma

**Review of preoperative transarterial chemoembolization for resectable hepatocellular carcinoma**

Zhi-Hui Gao, Dou-Sheng Bai, Guo-Qing Jiang, Sheng-Jie Jin

**Zhi-Hui Gao, Dou-Sheng Bai, Guo-Qing Jiang, Sheng-Jie Jin,** Hepato-bilio-pancreatic Surgery Department, Subei People’s Hospital, Yangzhou University, Yangzhou 225001, Jiangsu Province, China

**Author contributions:** Gao ZH and Bai DS performed the majority of the work for this review; Bai DS designed the review; Gao ZH wrote the manuscript; Jiang GQ and Jin SJ assisted with designing, literature searching and manuscript editing.

**Correspondence to: Dou-Sheng Bai, MD, Professor, Chief,** Hepato-bilio-pancreatic Surgery Department, Subei People’s Hospital, Yangzhou University, 98 Nantong West Road, Yangzhou225001, Jiangsu Province, China. bdsno1@hotmail.com

**Telephone:** +86-514-87373375 **Fax:** +86-514-87990188

**Received:** July 20, 2014  **Revised:** October 28, 2014

**Accepted:** November 17, 2014

**Published online:**

**Abstract**

Hepatocellular carcinoma (HCC) is one of the few cancers whose incidence has been continually increasing over recent years. Resection of HCC offers the only hope for cure. However, recurrences are common in patients who have undergone resection. In our opinion, the effectiveness with which transarterial chemoembolization (TACE) as a neoadjuvant therapy for resectable HCC prevents recurrence and prolongs survival has not been conclusively demonstrated. All published meta-analyses have consistently failed to demonstrate that preoperative TACE improves the prognosis of resectable HCC. We believe that these published articles have several limitations and have our own views about the results of meta-analyses. It is very important that the scientific community shed more light on the pathogenesis of HCC and relate this to choice of therapy. This review mainly concerns our understanding of preoperative TACE for resectable HCC and briefly addresses desirable directions for future studies.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Hepatocellular carcinoma; Surgical resection; Transarterial chemoembolization; Preoperative; Review

**Core tip:** Hepatocellular carcinoma (HCC) is the sixth most common neoplasm and third most frequent cause of cancer deaths. Resection of HCC offers the only hope for a cure, yet post-resection recurrence is common. The effectiveness of transarterial chemoembolization (TACE) as a neoadjuvant therapy for resectable HCC has not been conclusively demonstrated. All published meta-analyses have consistently failed to demonstrate its effectiveness. We believe these articles have several limitations and TACE is theoretically helpful in multinodular or infiltrative types of HCC.

Gao ZH, Bai DS, Jiang GQ, Jin SJ. Review of preoperative transarterial chemoembolization for resectable hepatocellular carcinoma. *World J Hepatol* 2014; In press

**INTRODUCTION**

Hepatocellular carcinoma (HCC), the commonest primary liver malignancy, sixth most common neoplasm, and third most frequent cause of cancer deaths, is increasing in incidence and prevalence both nationally and internationally. Potentially curative treatments for HCC include surgical resection, liver transplantation, and local ablative therapy. Among these, hepatectomy is considered the standard treatment for offering a chance of cure to patients with preserved liver function[1-3]. However, long-term survival after hepatectomy is unsatisfactory because of the high incidence of tumor recurrence. Even after radical surgery, tumor recurrence occurs in 75%–100% of HCC patients and is their major cause of death. This has led to many efforts to devise effective therapeutic strategies aimed at controlling tumor recurrence and thus prolonging long-term survival after HCC resection[4].

With improvements in interventional radiology, transarterial embolization (TAE) and transarterial chemoembolization (TACE) have been advocated as standard loco-regional palliative treatments for inoperable HCC. Some researchers believe that combining TACE and hepatectomy would improve long-term outcomes. This possibility has generated significant debate and numerous studies of the combination of TACE and curative resection for HCC since it was first described in the early 1990s. Some clinicians have attempted to employ TACE preoperatively as a loco-regional therapy to affect the course of the disease by decreasing tumor size, inducing tumor necrosis and by preventing tumor cell dissemination during surgery. However, others feel that this rationale may not be justified, and if the tumor is already resectable, administering TACE may complicate liver mobilization owing to the perihepatic adhesions that may occur following the TACE procedure[5-8]. This review summarizes current published reports linking TACE or TAE with surgical resection of HCC with the aim to suggest generally acceptable guidelines.

**CONTROVERSIAL RESULTS OF PREOPERATIVE TACE**

HCC commonly arises in patients with chronic viral or alcoholic liver disease: these patients’ livers are likely to harbor multiple and independent clones of premalignant cells and, when these cells are further exposed to carcinogenic insults, unicentric or multicentric carcinogenesis follows. Intrahepatic recurrence can represent either *de novo* tumor formation or intrahepatic metastasis of a clonally identical neoplasm. Early recurrence is primarily attributable to intrahepatic metastases, whereas late recurrence tends to be multicentric in origin. No matter how recurrences occur, it is generally believed that recurrences in the early postoperative period arise not because of inadequate resection of the primary tumor but either because of pre-existing microscopic tumor foci that were not detected by imaging modalities or because of malignant cells that were disseminated during surgical manipulation. Nowadays, the recurrence rate after resection is approximately 50% at 2 years and 75% at 5 years according to most series[9]. If any neoadjuvant therapy reduced the viability of HCC cells and prevented or effectively managed recurrences, the survival after resection of HCC would improve.

HCCs are supplied for the most part by the hepatic artery. Catheter-based techniques take advantage of this unusual architecture to deliver intra-arterial therapy directly to the tumor bed. Thus, TACE induces ischemic necrosis of tumors by arterial injection of chemotherapeutic drugs and embolizing agents. The aims of neoadjuvant therapy are to reduce tumor mass, thus making surgery easier, and destroy microscopic tumor foci and reduce the vascularity of tumors. Preoperative arterial injection of chemotherapeutic drugs and embolizing agents (TACE) reportedly can achieve all of the above-stated aims, as well as reduce the viability of HCC cells[10-12]. However, although several studies have demonstrated that preoperative TACE prevents tumor recurrence and prolongs survival in patients with HCC, others have failed to demonstrate these outcomes. Arguments against the use of preoperative TACE include: first, the associated complications, namely, liver function impairment and increased risk of liver failure; second, the associated delay in performing definitive surgery, during which time some resectable tumors become unresectable; third, this form of therapy mainly affects well-differentiated HCC and fails to completely kill poorly differentiated cells, thus the residual HCC cells are more aggressive; and last, incomplete HCC necrosis weakens adhesiveness within the tumor, thus facilitating the release of cancer cells from the primary tumor into the bloodstream. In addition, the effects of preoperative TACE on long-term outcome are controversial: it has not been proven that it prevents tumor recurrence and prolongs survival.

**SYSTEMATIC REVIEW AND META-ANALYSIS**

To produce more reliable evidence for clinical decision-making, randomized controlled studies and nonrandomized controlled studies have been subjected to meta-analysis. Several such meta-analyses provide the largest body of information currently available for assessing the role of preoperative TACE in patients with HCC. Their findings are mainly expressed in terms of disease-free and overall survival. To minimize heterogeneity, these studies have utilized strict inclusion criteria. For example, the most recently published meta-analysis, authored by Cheng *et al*[13], defined cure of HCC strictly as: (1) tumor had been resected; (2) negative surgical margins had been confirmed histologically; (3) no evidence of extrahepatic metastasis; and (4) no residual tumor according to dynamic contrast-enhanced CT or ultrasonography performed 3–5 wk postoperatively. All published meta-analyses have failed to show that preoperative TACE improves the prognosis[14-19]. Although the cited meta-analyses are well designed and conducted, and, more importantly, have reported consistent findings, we believe it is prudent to recommend TACE as a routine preoperative procedure for resectable HCC for the reasons explained below.

**NEW QUESTIONS AND IDEAS**

Although the mechanisms of recurrence after surgical resection of HCC remain controversial, it is noteworthy that early recurrence mainly takes the form of intrahepatic recurrence, which correlates strongly with tumor-related variables, whereas late recurrence mainly takes the form of multicentric foci, this correlating strongly with the condition of the remnant liver. Relevant tumor-related variables include vascular infiltration, tumor size, tumor capsule, and satellite nodules or dissemination of tumor cells during hepatectomy. Thus, both main tumor and the surrounding tissue may contain detectable or undetectable satellite nodules and the main route of early post-resection intrahepatic recurrence is spread via the portal vein. Clearly, hepatectomy cannot address all of these possibilities. In theory, TACE could; however, published meta-analyses studies do not support this contention[20-23].

However, the available studies have several limitations. We have found that the various meta-analyses use very heterogeneous definitions of resectable HCC. They also use different definitions of cure of HCC and different inclusion criteria. Thus, their findings indicate only that preoperative TACE does not improve the prognosis of resectable HCC as defined in that particular study.

Morphologic types of HCC include focal/nodular, massive, and diffuse/infiltrative. The infiltrative type accounts for 7%–15% of HCC cases. Although infiltrative HCC is not uncommon, especially in regions where hepatitis B virus is predominant, there are few published data concerning treatment of patients with this variant because infiltrative HCC almost always presents as an advanced diffuse tumor and surgery is therefore rarely indicated. The cumulative survival rates of patients with infiltrative HCC are reportedly 33.3% at 1 year and 13.6% at 3 years, independent of the treatment received[24-27]. About 15.9 % of reported patients with infiltrative HCC have undergone TACE repeatedly, with curative intent, and have survived more than 2 years. These long-term survivors are over 60 years old, have preserved hepatic function at the time of initial diagnosis, and have a major portal vein thrombosis without parasitic supply. In addition, published studies have also ignored the multinodular type of HCC[28-31]. Taking these observations into consideration allows the following improved understanding of the findings of published meta-analyses. First, TACE would indeed be helpful for treating small satellite nodules and destroying microscopic tumor foci, thus facilitating achievement of adequate resection, which would prolong the duration of survival. However, these considerations apply only in certain types of HCC, namely, to the best of our knowledge, multinodular and infiltrative types. Second, these are not the main types and have often been excluded from published meta-analyses. In conclusion, we still provocatively recommend preoperative TACE for resectable HCC, especially for multinodular and infiltrative types, to reduce recurrence rates. We also believe it is prudent to recommend TACE for patients with definite single nodular or massive HCC. We also recommend assessing the effects of preoperative TACE according to the various morphologic types.

**CONCLUSION**

We still cannot be certain whether preoperative TACE for resectable HCC is beneficial. Although we believe it is helpful in multinodular or infiltrative types of HCC, there is limited evidence for this. We believe it makes sense to assess the effects of preoperative TACE according to the various morphologic types. Thus, larger, well designed, randomized clinical trials are needed to detect realistically achievable treatment benefits.

**REFERENCES**

1 **Maluccio M**, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. *CA Cancer J Clin* 2012; **62**: 394-399 [PMID: 23070690 DOI: 10.3322/caac.21161]

2 **Kim HY**, Park JW. Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future. *Liver Cancer* 2014; **3**: 9-17 [PMID: 24804173 DOI: 10.1159/000343854]

3 **Zheng YB**, Meng QW, Zhao W, Liu B, Huang JW, He X, Li Y, Hu BS, Lu LG. Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. *Med Oncol* 2014; **31**: 843 [PMID: 24442426 DOI: 10.1007/s12032-014-0843-5]

4 **Kaibori M**, Tanigawa N, Kariya S, Ikeda H, Nakahashi Y, Hirohara J, Koreeda C, Seki T, Sawada S, Okazaki K, Kwon AH. A prospective randomized controlled trial of preoperative whole-liver chemolipiodolization for hepatocellular carcinoma. *Dig Dis Sci* 2012; **57**: 1404-1412 [PMID: 22271410 DOI: 10.1007/s10620-012-2029-3]

5 **Zhang L**, Hu P, Chen X, Bie P. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. *PLoS One* 2014; **9**: e100305 [PMID: 24945380]

6 **Chen BB**, Shih IL, Wu CH, Hsu C, Chen CH, Shih TT, Liu KL, Liang PC. Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies. *J Vasc Interv Radiol* 2014; **25**: 371-378 [PMID: 24468045 DOI: 0.1016/j.jvir.2013.10.027]

7 **Roayaie S**. TACE vs. surgical resection for BCLC stage B HCC. *J Hepatol* 2014; **61**: 3-4 [PMID: 24727122 DOI: 10.1016/j.jhep.2014.04.005]

8 **Zhang L**, Yin X, Gan YH, Zhang BH, Zhang JB, Chen Y, Xie XY, Ge NL, Wang YH, Ye SL, Ren ZG. Radiofrequency ablation following first-line transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria. *BMC Gastroenterol* 2014; **14**: 11 [PMID: 24410841 DOI: 10.1186/1471-230X-14-11]

9 **Gluer AM**, Cocco N, Laurence JM, Johnston ES, Hollands MJ, Pleass HC, Richardson AJ, Lam VW. Systematic review of actual 10-year survival following resection for hepatocellular carcinoma. *HPB* (Oxford) 2012; **14**: 285-290 [PMID: 22487065 DOI: 10.1111/j.1477-2574.2012.00446.x]

10 **Fiore F**, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F, Di Sarno A, Carratù AC, de Luca di Roseto C, Colao A, Faggiano A. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. *Endocrine* 2014; **47**: 177-182 [PMID: 24385266 DOI: 10.1007/s12020-013-0130-9]

11 **Kim JW**, Kim JH, Sung KB, Ko HK, Shin JH, Kim PN, Choi HK, Ko GY, Yoon HK, Chun SY, Gwon DI. Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2 cm or smaller. *Am J Gastroenterol* 2014; **109**: 1234-1240 [PMID: 24935276 DOI: 10.1038/ajg.2014.152]

12 **Cheung TT**, Poon RT, Jenkins CR, Chu FS, Chok KS, Chan AC, Tsang SH, Dai WC, Yau TC, Chan SC, Fan ST, Lo CM. Survival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas. *Liver Int* 2014; **34**: e136-e143 [PMID: 24451026 DOI: 10.1111/liv.12474]

13 **Cheng X**, Sun P, Hu QG, Song ZF, Xiong J, Zheng QC. Transarterial (chemo)embolization for curative resection of hepatocellular carcinoma: a systematic review and meta-analyses. *J Cancer Res Clin Oncol* 2014; **140**: 1159-1170 [PMID: 24752339 DOI: 10.1007/s00432-014-1677-4]

14 **Zhou WP**, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, Lau WY, Wu MC. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. *Ann Surg* 2009; **249**: 195-202 [PMID: 19212170 DOI: 10.1097/SLA.0b013e3181961c16]

15 **Choi J**, Shim JH, Shin YM, Kim KM, Lim YS, Lee HC. Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma. *J Hepatol* 2014; **60**: 1212-1218 [PMID: 24486088 DOI: 10.1016/j.jhep.2014.01.014]

16 **Beheshti MV**, Meek J. Calculation of operating expenses for conventional transarterial chemoembolization in an academic medical center: a step toward defining the value of transarterial chemoembolization. *J Vasc Interv Radiol* 2014; **25**: 567-574 [PMID: 24462006 DOI: 10.1016/j.jvir.2013.10.023]

17 **Zhou Y**, Zhang X, Wu L, Ye F, Su X, Shi L, Li B. Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma. *BMC Gastroenterol* 2013; **13**: 51 [PMID: 23509884 DOI: 10.1186/1471-230X-13-51]

18 **Sellers MT**, Huggins S, Kegley K, Pollinger HS, Shrestha R, Johnson MW, Stein LL, Panjala C, Tan M, Arepally A, Jacobs L, Caldwell C, Bosley M, Citron SJ. Multivariate analysis of prognostic factors for survival following doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. *J Vasc Interv Radiol* 2013; **24**: 647-654 [PMID: 23384831 DOI: 10.1016/j.jvir.2012.12.003]

19 **Chua TC**, Liauw W, Saxena A, Chu F, Glenn D, Chai A, Morris DL. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. *Liver Int* 2010; **30**: 166-174 [PMID: 19912531 DOI: 10.1111/j.1478-3231.2009.02166.x]

20 **Jang ES**, Yoon JH, Chung JW, Cho EJ, Yu SJ, Lee JH, Kim YJ, Lee HS, Kim CY. Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization. *J Cancer Res Clin Oncol* 2013; **139**: 635-643 [PMID: 23283527 DOI: 10.1007/s00432-012-1364-2]

21 **Rosenkrantz AB**, Lee L, Matza BW, Kim S. Infiltrative hepatocellular carcinoma: comparison of MRI sequences for lesion conspicuity. *Clin Radiol* 2012; **67**: e105-e111 [PMID: 23026725 DOI: 10.1016/j.crad.2012.08.019]

22 **Mehta N**, Fidelman N, Sarkar M, Yao FY. Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2013; **11**: 572-578 [PMID: 23333661 DOI: 10.1016/j.cgh.2012.12.030]

23 **Mathews P**, Lee D, Chung YH, Kim JA, Lee JH, Jin YJ, Park W, Lyu H, Jaffee E, Zheng L, Yu E, Lee YJ. Effects of genomic changes in hepatitis B virus on postoperative recurrence and survival in patients with hepatocellular carcinoma. *Ann Surg Oncol* 2013; **20**: 1216-1222 [PMID: 23104706 DOI: 10.1245/s10434-012-2706-7]

24 **Liu L**, Wang W, Chen H, Zhao Y, Bai W, Yin Z, He C, Jia J, Yang M, Xia J, Fan D, Han G. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma. *Clin Cancer Res* 2014; **20**: 1623-1631 [PMID: 24493832 DOI: 10.1158/1078-0432.CCR-13-1716]

25 **Kneuertz PJ**, Demirjian A, Firoozmand A, Corona-Villalobos C, Bhagat N, Herman J, Cameron A, Gurakar A, Cosgrove D, Choti MA, Geschwind JF, Kamel IR, Pawlik TM. Diffuse infiltrative hepatocellular carcinoma: assessment of presentation, treatment, and outcomes. *Ann Surg Oncol* 2012; **19**: 2897-2907 [PMID: 22476754 DOI: 10.1245/s10434-012-2336-0]

26 **Lee D**, Chung YH, Kim JA, Lee YS, Lee D, Jang MK, Kim KM, Lim YS, Lee HC, Lee YS. Transforming growth factor beta 1 overexpression is closely related to invasiveness of hepatocellular carcinoma. *Oncology* 2012; **82**: 11-18 [PMID: 22269311 DOI: 10.1159/000335605]

27 **Liu L**, Zhang C, Zhao Y, Qi X, Chen H, Bai W, He C, Guo W, Yin Z, Fan D, Han G. Transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis: prognostic factors in a single-center study of 188 patients. *Biomed Res Int* 2014; **2014**: 194278 [PMID: 24800212 DOI: 10.1155/2014/194278]

28 **Liu PH**, Lee YH, Hsia CY, Hsu CY, Huang YH, Chiou YY, Lin HC, Huo TI. Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. *Ann Surg Oncol* 2014; **21**: 1825-1833 [PMID: 24499831 DOI: 10.1245/s10434-014-3510-3]

29 **Jin YJ**, Lee JW, Choi YJ, Chung HJ, Kim YS, Lee KY, Ahn SI, Shin WY, Cho SG, Jeon YS. Surgery versus transarterial chemoembolization for solitary large hepatocellular carcinoma of BCLC stage A. *J Gastrointest Surg* 2014; **18**: 555-561 [PMID: 24420729 DOI: 10.1007/s11605-013-2440-x]

30 **Du ZG**, Wei YG, Chen KF, Li B. Risk factors associated with early and late recurrence after curative resection of hepatocellular carcinoma: a single institution's experience with 398 consecutive patients. *Hepatobiliary Pancreat Dis Int* 2014; **13**: 153-161 [PMID: 24686542]

31 **Kokabi N**, Camacho JC, Xing M, Qiu D, Kitajima H, Mittal PK, Kim HS. Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis. *Abdom Imaging* 2014; **39**: 969-978 [PMID: 24740759 DOI: 10.1007/s00261-014-0127-8]

**P-Reviewer:** Bester L **S-Editor:** Qi Y **L-Editor: E-Editor:**